Adolescents and young adults with cancer: the clinical course of COVID-19 infections

Authors

Julie A. Wolfson, Division of Pediatric Hematology-Oncology
Elizabeth S. Davis, Boston Medical Center
Aniket Saha, Greenville Hospital System
Isaac Martinez, The University of Alabama at Birmingham
David McCall, The University of Texas MD Anderson Cancer Center
Prachi Kothari, The Children's Hospital of Philadelphia
Prachi Kothari, The Children's Hospital of Philadelphia
Julienne Brackett, Texas Children's Hospital
David S. Dickens, University of Iowa Carver College of Medicine
Alissa R. Kahn, St. Joseph's University Medical Center
Carla Schwalm, Bronson Methodist Hospital
Carla Schwalm, Bronson Methodist Hospital
Archana Sharma, Rutgers Cancer Institute of New Jersey
Joshua Richman, The University of Alabama at Birmingham
Branko Cuglievan, The University of Texas MD Anderson Cancer Center
Smita Bhatia, Division of Pediatric Hematology-Oncology
Chen Dai, The University of Alabama at Birmingham
Jennifer M. Levine, Childrens National Health System
Emily E. Johnston, Division of Pediatric Hematology-Oncology
Catherine Aftandilian, Stanford University
Anurag K. Agrawal, UCSF Benioff Children's Hospital Oakland
Guillermo De Angulo, Nicklaus Children's Hospital
Paula Aristizabal, Department of Pediatrics
Kayleen Bailey, Icahn School of Medicine at Mount Sinai
Jenna K. Bardwell, The University of Chicago
David L. Becton, Arkansas Children's Hospital
Christina J. Bemrich-Stolz, The University of Alabama at Birmingham
Lauren H. Boal, Massachusetts General Hospital
Pinki K. Prasad, LSU Health Sciences Center - New OrleansFollow
et al

Document Type

Article

Publication Date

8-1-2024

Publication Title

Journal of the National Cancer Institute

Abstract

Adolescents and young adults (ie, individuals aged 15-39 years, known as AYAs) with cancer face unique vulnerabilities yet remain underrepresented in clinical trials, including adult registries of COVID-19 in cancer (AYAs: 8%-12%). We used the Pediatric Oncology COVID-19 Case Report to examine the clinical course of COVID-19 among AYAs with cancer. The Pediatric Oncology COVID-19 Case Report collects deidentified clinical and sociodemographic data regarding individuals aged from birth to 39 years with cancer (37%) and COVID-19 from more than 100 institutions. Between April 1, 2020, and November 28, 2023, 191 older AYAs (individuals 22-39 years of age) and 640 younger AYAs (individuals 15-21 years of age) were captured. Older AYAs were less often hospitalized (P < .001), admitted to the intensive care unit (P = .02), and required respiratory support (P = .057). In multivariable analyses, older AYAs faced 80% lower odds of intensive care unit admission but 2.3-times greater odds of changes to cancer-directed therapy. Unvaccinated patients had 5.4-times higher odds of intensive care unit admission. Among AYAs with cancer, the COVID-19 course varies by age. These findings can inform oncology teams directing COVID-19 management and prevention in AYA patients with cancer.

First Page

1366

Last Page

1373

PubMed ID

38627241

Volume

116

Issue

8

Comments

See article for full author list

Recommended Citation

Wolfson, Julie A.; Davis, Elizabeth S.; Saha, Aniket; Martinez, Isaac; McCall, David; Kothari, Prachi; Kothari, Prachi; Brackett, Julienne; Dickens, David S.; Kahn, Alissa R.; Schwalm, Carla; Schwalm, Carla; Sharma, Archana; Richman, Joshua; Cuglievan, Branko; Bhatia, Smita; Dai, Chen; Levine, Jennifer M.; Johnston, Emily E.; Aftandilian, Catherine; Agrawal, Anurag K.; De Angulo, Guillermo; Aristizabal, Paula; Bailey, Kayleen; Bardwell, Jenna K.; Becton, David L.; Bemrich-Stolz, Christina J.; Boal, Lauren H.; Prasad, Pinki K.; and al, et, "Adolescents and young adults with cancer: the clinical course of COVID-19 infections" (2024). School of Medicine Faculty Publications. 2869.
https://digitalscholar.lsuhsc.edu/som_facpubs/2869
10.1093/jnci/djae085